Deimmunization

Known as: De-immunization 
A laboratory procedure where the gene encoding a therapeutic recombinant protein is manipulated to minimize the immunogenicity of the protein. This… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
02420052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Recombinant immunotoxins (RITs) are genetically engineered proteins being developed to treat cancer. They are composed of an Fv… (More)
Is this relevant?
2015
2015
Anti-drug immune responses are a unique risk factor for biotherapeutics, and undesired immunogenicity can alter pharmacokinetics… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2015
2015
BACKGROUND Targeted toxins require multiple treatments and therefore must be deimmunized. We report a method of protein… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Therapeutic proteins continue to yield revolutionary new treatments for a growing spectrum of human disease, but the development… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
T cell-dependent development of anti-Factor VIII (FVIII) antibodies that neutralize FVIII activity is a major obstacle to… (More)
Is this relevant?
2012
2012
The unparalleled specificity and activity of therapeutic proteins has reshaped many aspects of modern clinical practice, and… (More)
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
Is this relevant?
2011
2011
A number of heterologous enzymes have been investigated for cancer treatment and other therapeutic applications; however… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
Is this relevant?
2009
2009
Immunogenicity is a major limitation to therapy with certain monoclonal antibodies and proteins. A major driver for… (More)
Is this relevant?
2009
2009
To develop protein therapeutics from exogenous sources, it is necessary to mitigate the risks of eliciting an anti-biotherapeutic… (More)
Is this relevant?
2006
2006
Self-proteins in the extracellular environment are constantly sampled and processed through the Class II antigen presentation… (More)
Is this relevant?